Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute leukemia (AML/ALL) or advanced MDS (INT-2 or high risk) in complete remission (CR/CRc/CRi) documented by bone marrow biopsy done within 30 days prior to the initiation of conditioning regimen.~* Available HLA-haploidentical donor that meets the following criteria:~  * Immediate family member (sibling, offspring, or parent)~ * At least 18 years of age~ * HLA-haploidentical donor/recipient match by class I serologic typing at the A\&B locus.~ * In the treating physician's opinion, is in general good health, and medically able to tolerate leukapheresis required for harvesting HSC~ * No active hepatitis (B, C), HTLV, and HIV infections~ * Not pregnant~* Karnofsky performance status ≥ 70 %~* Adequate organ function as defined below:~  * Total bilirubin ≤ 2.5 mg/dl (unless the patient has a history of Gilbert's syndrome)~ * AST(SGOT) and ALT(SGPT) ≤ 3.0 x IULN~ * Creatinine ≤ 2.0 x IULN OR estimated creatinine clearance ≥ 30 mL/min/1.73 m\^2 by Cockcroft-Gault Formula~ * Oxygen saturation ≥ 90% on room air~ * LVEF ≥ 40%~ * FEV1 and FVC ≥ 50% predicted, corrected DLCO ≥ 40% predicted~* At least 18 years of age at the time of study registration~* Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable)~Exclusion Criteria:~* Recipients with donor sensitive antibodies (DSA), defined by 2000 or higher MFI against one or more class I or II antigens~* Known HIV or active Hepatitis B or C infection~* Underwent a previous related or unrelated allogeneic transplant~* Known hypersensitivity to one or more of the study agents~* Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of the conditioning regimen.~* Pregnant and/or breastfeeding~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or unstable cardiac arrhythmias.~* Presence of a readily available 6/6 matched sibling donor who is a candidate for donation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Azacitidine (Type: EXPERIMENTAL): * Treating physician must choose from one of these conditioning regimens (will be given per standard of care)~  * fludarabine and fractionated total body irradiation (Flu/FrTBI)~ * fludarabine and busulfan (Flu/Bu4)~ * fludarabine, cyclophosphamide, and single dose total body irradiation (Flu/Cy/sdTBI)~ * fludarabine and melphalan (Flu/Mel)~ * reduced-intensity fludarabine and busulfan (Flu/Bu2)~* G-CSF from Day -5 through Day -1 per standard of care~* On Day 0, the allograft will be infused per standard of care.~* Azacitidine will be administered on Day +1 and +2 post-stem cell transfusion days~* Cyclophosphamide on Days +3 and +4 post-transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues